Biohaven Pharmaceutical Holding Co Ltd.
DelistedCIK 1689813fmd_0G0Q49QG2RA7YZV379MEAZM7BNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2022, 27 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | 64 | 463 |
| Cost of revenue | – | – | – | 0 | 0 | 18 | 92 |
| Gross profit | – | – | – | 0 | 0 | 46 | 371 |
| Research and development | 8 | 56 | 89 | 190 | 345 | 229 | 361 |
| Selling, general and administrative | – | – | – | 35 | 134 | 462 | 714 |
| Total operating expenses | 10 | 61 | 108 | 225 | 479 | 691 | 1,075 |
| Operating income | (10) | (61) | (108) | (225) | (479) | (645) | (704) |
| Interest expense | – | 0 | 0 | 0 | 13 | 28 | 32 |
| Interest and investment income | – | – | – | – | – | 0 | 0 |
| Other non-operating income (expense) | (0) | (3) | (19) | (16) | (49) | (113) | (139) |
| Income before taxes | (10) | (63) | (126) | (240) | (528) | (758) | (843) |
| Income tax expense | – | 0 | 1 | 0 | 0 | 10 | 5 |
| Net income from continuing operations | – | (64) | (127) | (241) | (529) | (769) | (848) |
| Net income | (10) | (64) | (127) | (241) | (529) | (767) | (847) |
| Net income to common shareholders | (10) | (64) | (139) | (241) | (529) | – | – |